Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer

On August 27, 2026 Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, reported new data showing its lead asset, paxalisib, achieved a 100% clinical benefit rate in six evaluable patients with Stage IV triple-negative breast cancer (TNBC). Five of the six patients achieved an objective response – a measurable 30% or greater reduction in tumor burden after treatment – including one complete response and four partial responses, resulting in an objective response rate of 83 percent. The remaining patient achieved stable disease. Importantly, these results were achieved with the convenience of oral dosing and a favorable safety and tolerability profile, with no paxalisib-related serious adverse events and no grade 3 or higher hyperglycemia, stomatitis or mucositis, toxicities commonly associated with PI3K/mTOR pathway inhibition.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Metastatic triple-negative breast cancer is one of the toughest cancers to treat. Historically, only 12 percent of patients are alive five years after diagnosis. Once a patient’s disease progresses on immunotherapy, options run out quickly," said Dr. John Friend, CEO, Kazia Therapeutics. "Across the six evaluable patients treated, every one of them has benefited, and we haven’t seen a single serious adverse event tied to paxalisib. We’ve also demonstrated meaningful improvements in terminally exhausted T cells and drastic reductions in circulating tumor cell (CTC) clusters, providing early evidence that paxalisib may be addressing biological mechanisms associated with treatment resistance and metastasis. These results strengthen our confidence in this program as we continue enrollment in the Phase 1b trial."

Clinical responses were observed across a broad range of metastatic disease sites, including lung, liver, bone, lymph node and central nervous system target lesions, with responses emerging as early as approximately three months post-randomization. Most notably, a 44-year-old woman with Stage IV TNBC achieved a complete metabolic response and has had no evidence of disease since November 2025. Her response has remained durable through the most recent assessment and has been accompanied by sustained and complete abolishment of CTC clusters and significant reduction in terminally exhausted CD8+ T cells, alongside overall improvement in markers of immune function.

Translational analyses demonstrated reductions in terminally exhausted CD8+ T cells across all six patients, with a median reduction of 51 percent within approximately three weeks of treatment. These cells represent a dysfunctional population of cytotoxic T cells that has lost its ability to recognize and kill cancer cells. Notably, total CD8+ T cell counts remained unchanged, which suggests that paxalisib is not eliminating these exhausted cells or replacing them with new ones. Instead, the existing cells appear to be regaining function. Blood-based simultaneous multi-modal protein, RNA and plasma profiling supported this finding, demonstrating increases in immune cell populations associated with anti-tumor activity, reductions in markers of immune exhaustion and evidence of PI3K-AKT pathway target engagement. The marker findings provide evidence of improved overall immune function across all patients.

In parallel with the immune changes, all six patients demonstrated reductions in circulating tumor cell clusters, which are aggressive groupings of tumor cells in the bloodstream associated with metastatic spread. The median reduction was 83 percent within six to seven weeks of treatment.

"Two of the biggest challenges in treating triple-negative breast cancer are the dormant cancer cells that spread through the bloodstream, and an immune system too exhausted to fight them. It’s rare to see a treatment influence both at the same time. After years of studying this disease, it’s exciting to witness this in a clinical setting. The circulating tumor cell clusters that seed new metastases are being suppressed, while the exhausted T cells needed to fight the cancer are recovering function and showing signs of immune memory which may translate to more durable responses. These changes in the blood are tracking with what we are seeing on the scans, which suggests our liquid biopsy approach may be capturing both the tumor’s metastatic behavior and the immune system’s response to treatment in real time. It gives us a remarkable window into the disease, and we look forward to building on these findings as the trial progresses," said Dr. Sudha Rao, Chief Scientific Officer, Kazia Therapeutics.

These early biological findings represent what may be a first-in-class effect and suggest that paxalisib’s therapeutic effect may extend beyond cytoplasmic PI3K/mTOR inhibition. The rapid and consistent biological responses observed across all evaluable patients support the hypothesis that paxalisib may exert dual influence by restoring immune function and reducing metastatic dissemination, addressing two of the greatest challenges in the treatment of triple-negative breast cancer and fundamental drivers of cancer progression.

Enrollment in the Company’s ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab (Keytruda) and chemotherapy in advanced metastatic TNBC is expected to be completed by July 2027, with interim clinical updates anticipated throughout 2026 and 2027.

(Press release, Kazia Therapeutics, AUG 27, 2026, View Source [SID1234670379])

Akari Therapeutics Participates in the Virtual Investor “Why Now” On-Demand Conference

On August 27, 2026 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, reported that it participated in the Virtual Investor "Why Now" on-demand conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the webcast, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, presented the Company’s investment thesis, highlighting why he believes now is a pivotal time for Akari. The discussion highlights the rapidly evolving ADC landscape, increasing industry demand for differentiated payload technologies, and Akari’s proprietary PH1 RNA splicing payload platform, which is designed to address limitations associated with conventional ADC payloads.

The video webcast is now accessible for on-demand viewing here.

JTC Team and Virtual Investor Co. are paid consultants to Akari Therapeutics, Plc. JTC Team and Virtual Investor Co. are investor relations and corporate communications firms. Any content included in this release shall not be construed as an offer to purchase securities of Akari Therapeutics, Plc. Interested parties are responsible for conducting their own due diligence and are encouraged to review the Company’s website and the SEC website for the latest information and filings on the Company.

(Press release, Akari Therapeutics, AUG 27, 2026, View Source [SID1234670378])

AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference

On August 27, 2026 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") reported that it participated in the Virtual Investor "Why Now" on-demand conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the webcast, AIM Chief Executive Officer Thomas Equels presented the Company’s investment thesis, highlighting why he believes now is a pivotal time for AIM. The presentation discusses the Company’s progress advancing Ampligen through the Phase 2 DURIPANC clinical trial in metastatic pancreatic cancer, including successful completion of enrollment ahead of schedule, Ampligen dosing of the final patient and the anticipated transition into primary endpoint evaluation in the fourth quarter of 2026, with topline results expected in the first quarter of 2027.

The video webcast is now accessible for on-demand viewing here.

JTC Team and Virtual Investor Co. are paid consultants to AIM ImmunoTech Inc. JTC Team and Virtual Investor Co. are investor relations and corporate communications firms. Any content included in this release shall not be construed as an offer to purchase securities of AIM ImmunoTech Inc. Interested parties are responsible for conducting their own due diligence and are encouraged to review the Company’s website and the SEC website for the latest information and filings on the Company.

(Press release, AIM ImmunoTech, AUG 27, 2026, View Source [SID1234670377])

Faron Announces First Patient Enrolled in BEXAR Investigator-Initiated Trial

On August 27, 2026 Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient’s own immune system, reported that the first patient has been enrolled in the Phase 1b/2 BEXAR investigator-initiated trial.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The BEXAR trial evaluates Faron’s lead asset, bexmarilimab, in combination with standard-of-care doxorubicin as a first-line treatment for patients with metastatic soft-tissue sarcoma.

The trial is sponsored by the international oncology research company MEDSIR and currently conducted at six hospitals across Spain, led by the Vall d’Hebron University Hospital in Barcelona. The Phase 1b/2 BEXAR trial is designed to evaluate the safety and tolerability of bexmarilimab in combination with doxorubicin in the Phase 1b stage, followed by a contingent randomized Phase 2 assessment of preliminary efficacy versus doxorubicin alone.

Dr. César Serrano, Group Leader of the Sarcoma Translational Research Program at the Vall d’Hebron Institute of Oncology and a member of the Sarcoma Faculty of the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper), and scientific and clinical lead of the trial said, "Metastatic soft-tissue sarcoma has seen limited therapeutic progress in decades, and remains particularly difficult to treat. By combining doxorubicin with bexmarilimab, we aim to test whether reprogramming immunosuppressive macrophages can help ignite an anti-tumor response and translate into clinical benefit."

This enrollment marks the first patient treated with bexmarilimab in the BEXAR trial and the first clinical evaluation of an anti-Clever-1 strategy in combination with doxorubicin in patients with soft-tissue sarcoma. Soft-tissue sarcomas are highly aggressive malignancies and many subtypes are characterized by an immunologically inactive tumor microenvironment heavily dominated by immunosuppressive macrophages. These tumors express some of the highest levels of Clever-1, the target receptor of bexmarilimab, providing a strong mechanistic rationale for this combination strategy.

Dr. Petri Bono, Chief Medical Officer at Faron, commented, "The initiation of patient enrollment in the BEXAR trial is a significant milestone for our solid tumor strategy. Sarcomas express exceptionally high levels of Clever-1, providing a strong biological rationale for investigating an anti-Clever-1 approach in this setting. By combining bexmarilimab with chemotherapy, this trial is the first opportunity to generate clinical evidence for bexmarilimab’s mechanism in soft-tissue sarcomas. If this combination shows evidence of synergy, it could support the rationale for exploring bexmarilimab with other chemotherapy backbones across Clever-1-expressing tumor types. We are proud to support the world-class team at Vall d’Hebron and look forward to the data this trial will generate."

About bexmarilimab

Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes by targeting myeloid cell function. It binds to Clever-1, a receptor on immunosuppressive macrophages that helps cancer evade the immune system. By targeting Clever-1, bexmarilimab reprograms the tumor microenvironment to ignite a potent anti-tumor immune response.

(Press release, Faron Pharmaceuticals, AUG 27, 2026, View Source [SID1234670362])

Oncoinvent presents first half 2026 results

On August 27, 2026 Oncoinvent reported that its management will give an online presentation to investors, analysts and the press at 10:00am CEST. It will be possible to submit questions during the presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presenters: CEO Oystein Soug, CFO Ramzi Amri
Time: 10:00am CEST
Webcast link: View Source
A recording of the webcast will be made available on www.oncoinvent.com after the live sending.

Highlights:

Achieved 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin
Added four new clinical sites to Oncoinvent’s Phase 2 trial
Presented positive 24-month follow-up data from Phase 1 ovarian cancer trial of Radspherin at 27th Congress of the European Society of Gynaecological Oncology (ESGO) 2026
Appointed Dr Ramzi Amri as Chief Financial Officer (CFO)
Secured new patent expanding protection for Radspherin
Post-period highlights:

Announced publication of normal tissue dosimetry results in Journal of Nuclear Medicine
Announced abstracts accepted at two major scientific conferences:
European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026 in Madrid, Spain (23-27 October)
European Association of Nuclear Medicine (EANM) Annual Congress 2026 in Vienna, Austria (17-21 October)
Oystein Soug, CEO, commented: "We entered the year with a clear focus on accelerating patient recruitment, and I am pleased to say that these efforts are delivering tangible results. Recruitment momentum accelerated significantly during the first half of the year, reinforcing our confidence in the potential of Radspherin to address a significant unmet medical need in ovarian cancer."

Key financial figures

AMOUNTS IN 1 000 NOK 1H 2026 1H 2025 FY2025
Total operating revenue 8 203 11 960 28 069
Total operating expenses (77 195) (63 978) (186 399)
Operating profit (-loss) (68 992) (52 018) (158 330)
Cash 108 839 77 412 179 670
Earnings per share (EPS) (15.20) (54.01) (125.13)
# Shares 4 478 412 962 544 1 239 249
Employees (FTEs) 42 36 44
The interim financial information has not been subject to audit

Reporting material:

Oncoinvent 1H26 report
Oncoinvent 1H26 presentation
The reporting material are also available in the Investor Relations section of the Company’s website at www.oncoinvent.com.

(Press release, Oncoinvent, AUG 27, 2026, https://www.oncoinvent.com/press-release/oncoinvent-presents-first-half-2026-results/ [SID1234670350])